|

Pelcitoclax Clinical Trials

1 actively recruiting trial across 1 location

Also known as: APG 1252, APG-1252, APG1252, Bcl-2/Bcl-XL Inhibitor APG-1252

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v81
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v81
  • Recurrent Primary Peritoneal Carcinoma1
  • Recurrent Platinum-Resistant Ovarian Carcinoma1
  • Recurrent Fallopian Tube Carcinoma1

Atlanta, Georgia1 trial

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Emory University Hospital/Winship Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.